HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPα signaling
© Zhao et al.; licensee BioMed Central Ltd. 2013
Received: 27 July 2013
Accepted: 11 December 2013
Published: 21 December 2013
Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus etiologically associated with adult T-cell leukemia (ATL). The HTLV-1 bZIP factor (HBZ), which is encoded by minus strand of provirus, is expressed in all ATL cases and supports the proliferation of ATL cells. However, the precise mechanism of growth promoting activity of HBZ is poorly understood.
In this study, we showed that HBZ suppressed C/EBPα signaling activation induced by either Tax or C/EBPα. As mechanisms of HBZ-mediated C/EBPα inhibition, we found that HBZ physically interacted with C/EBPα and diminished its DNA binding capacity. Luciferase and immunoprecipitation assays revealed that HBZ repressed C/EBPα activation in a Smad3-dependent manner. In addition, C/EBPα was overexpressed in HTLV-1 infected cell lines and fresh ATL cases. HBZ was able to induce C/EBPα transcription by enhancing its promoter activity. Finally, HBZ selectively modulated the expression of C/EBPα target genes, leading to the impairment of C/EBPα-mediated cell growth suppression.
HBZ, by suppressing C/EBPα signaling, supports the proliferation of HTLV-1 infected cells, which is thought to be critical for oncogenesis.
KeywordsHTLV-1 HBZ C/EBPα
Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL) [1, 2]. HTLV-1 encodes several regulatory (tax and rex) and accessory (p12, p13 and p30) genes in the pX region located between the env and 3’ long terminal repeat (LTR) . Among the viral genes, Tax is thought to play a central role in the pathogenesis of HTLV-1 . Yet the expression of Tax cannot be detected in ~60% of fresh ATL cases due to epigenetic modifications or deletion of the 5’LTR . In contrast, the HTLV-1 bZIP factor (HBZ), which is encoded by the minus strand of the HTLV-1 genome, is expressed in all ATL cases and supports the proliferation of HTLV-1 infected cells [6–8]. HTLV-2, a type of retrovirus which is similar with HTLV-1, encodes an antisense protein (APH-2) using the minus strand of its genome. However, APH-2 does not seem to promote cell proliferation [9, 10]. HBZ was reported to repress Tax-mediated transactivation of viral transcription from the HTLV-1 5’LTR . Moreover, HBZ dysregulated multiple cellular signalings including the classical pathway of NF-κB, TGF-β, AP-1, and the Wnt pathways, which is likely to contribute to viral persistence and clonal expansion of infected cells [12–15].
The CCAAT/enhancer binding protein (C/EBP) family of proteins represents a critical group of bZIP transcription factors that are key to the regulation of cell proliferation, development, and immune responses [16, 17]. Dysregulated C/EBP signaling is intimately associated with tumorigenesis and viral diseases . Furthermore, the ability of C/EBPs to direct cellular fate is thought to depend on the presence of specific collaborating transcription factors, and allows C/EBPs to act as both tumor suppressors and tumor promoters under different conditions . C/EBPα, the founding member of this family, has been demonstrated to be important for differentiation of several cell types . On the other hand, C/EBPα emerged as an important negative regulator of cell proliferation . Thus, most tumors have evolved distinct strategies to attenuate C/EBPα function [17, 21]. Known mechanisms of C/EBPα suppression in cancer cells include (1) transcriptional downregulation of CEBPA expression; (2) point mutations and deletions in C/EBPα; and (3) inhibition of C/EBPα transcriptional activation through protein-protein interaction. However, normal C/EBPα is overexpressed in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and inhibits apoptosis by upregulating bcl-2 and FLIP expression [22, 23]. It suggested that C/EBPα may exhibit oncogenic as well as tumour suppressor properties in human leukaemogenesis.
In ATL, Tax has been shown to bind to CCAAT binding proteins such as nuclear factor YB subunit (NF-YB) and C/EBPβ . Through its association with NF-YB, Tax activates the major histocompatibility complex class II (MHC-II) promoter . Additionally, C/EBPβ was capable of inhibiting Tax-dependent transactivation of the HTLV-1 LTR, as well as efficiently decreasing Tax synthesis from an infectious HTLV-1 molecular clone . On the other hand, expression of Tax increases binding of C/EBPβ to and activates the IL-1β promoter . Interestingly, previously published microarray data showed that the CEBPA gene was overexpressed in adult T-cell leukemia cells [27, 28]. It is thus likely that the dysregulated C/EBP signaling pathway may play a role in ATL.
Although regulation of C/EBP signaling by Tax has been reported, little is known about whether other viral proteins affect C/EBP signaling. In the present study, we found that HBZ suppressed C/EBP signaling by interacting with C/EBPα, resulting in the impairment of C/EBPα-mediated cell growth suppression. This might account for why HBZ supports the proliferation of HTLV-1 infected cells.
HBZ suppresses C/EBPα signaling
HBZ interacts with C/EBPα
HBZ depends on Smad3 to inhibit C/EBPα-mediated transcription
Domains of HBZ responsible for suppression of C/EBPα
C/EBPα is overexpressed in ATL
C/EBPα expression is induced by HBZ
HBZ overcomes C/EBPα-mediated suppression of T-cell proliferation
There results together indicate that HBZ supports the proliferation of T cells through dysregulation of C/EBPα signaling as well as selective modulation of transcription of C/EBPα target genes.
After transmission, HTLV-1 increases its viral copy number by clonal proliferation of infected cells and results in the onset of ATL [5, 35]. In this strategy, Tax was thought to play a critical role in increasing the number of HTLV-1-infected cells by promoting proliferation and inhibiting apoptosis [36, 37]. However, because Tax is the major target of cytotoxic T lymphocytes (CTLs), it is frequently inactivated by genetic and epigenetic modifications [5, 38]. Therefore, HTLV-1 has evolved mechanisms to maintain cell survival in a Tax-independent manner. We have reported that HBZ, which is consistently expressed in ATL, promotes the proliferation of T-lymphocytes in vitro, and increases splenic CD4+ T-cells in HBZ transgenic mice, indicating a role for HBZ, like tax, in the proliferation of HTLV-1 infected cells [7, 31]. So far, the mechanism by which HBZ promotes proliferation of leukemic cells has not been well elucidated. Accumulating evidence shows that C/EBPα possesses the ability to arrest cell proliferation through upregulation of CDKN1A (p21) as well as direct inhibition of E2F . We firstly present evidence that C/EBPα is highly expressed in ATL. However, C/EBPα’s growth-suppression function is impaired by HBZ, resulting in the proliferation of ATL cells despite C/EBPα expression. It is thus likely that HBZ may support the proliferation of HTLV-1 infected cells, whereas other mechanisms, which include dysregulation of C/EBPα signaling and selectively modulate C/EBPα target gene expression. In support of our hypothesis, we showed in this study that HBZ enhanced the expression of E2F1, PCNA, and DHFR genes in C/EBPα-expressing cells and did not interfere with MYC, CDKN1A, and CDK2 expression, contrary to the effect of C/EBPα alone .
Apart from the growth suppression function, C/EBP family proteins have oncogenic properties [17, 21]. Consistent with our findings, recent studies reported that overexpression of C/EBPα occurs in cancer, such as B precursor acute lymphoblastic leukemia (ALL) and a subset of human hepatocellular carcinomas (HCCs) [22, 40]. Importantly, C/EBPα induces BCL2 and FLIP gene expression in cooperation with NF-κB p50, allowing cancer cells to escape apoptosis . We showed here that C/EBPα was overexpressed in ATL, whereas its growth-suppressive function was impaired by the effect of HBZ. In this regard, it is meaningful to raise the question: why do ATL cells need high levels of C/EBPα? It has been reported that HBZ suppressed apoptosis of HTLV-1 infected cells, while the underlying mechanism is still unknown. As shown in Figure 7C, HBZ selectively suppressed the level of C/EBPα target genes which related with cell growth, but did not inhibit the C/EBPα-induced expression of anti-apoptotic genes including BCL2 and FLIP, suggesting that HBZ may fulfill its anti-apoptotic function through dysregulation of C/EBPα signaling.
Immunodeficiency in ATL patients is pronounced, and results in frequent opportunistic infections by various pathogens [41, 42]. As a mechanism of this immunodeficiency, HBZ has been shown to inhibit CD4 T-cell responses, resulting in impaired host immunity in vivo[31, 43]. Further study demonstrated that HBZ transgenic mice, which expressed excess amount of C/EBPα, were vulnerable to opportunistic pathogens . It was reported that a population of PD-1+ memory phenotype CD4+ T cell underlies the global depression of the T cell immune response, and such features are attributable to an unusual expression of C/EBPα . Like C/EBPα, C/EBPβ acts as a master regulator of the tolerogenic and immunosuppressive environment induced by cancer . Thus, our results now open the possibility that HBZ may induce the expression of C/EBPα, leading to immunodeficiency in ATL, and perhaps to oncogenesis. Further studies on C/EBP signaling in ATL are necessary to clarify its roles.
Many viruses have developed distinct strategies to modulate C/EBPα signaling using their own viral proteins. Examples include hepatitis B virus pX; Epstein-Barr virus BZLF; as well as human immunodeficiency virus TAT and Vpr [46–48]. Like HBZ, the HBV pX and EBV BZLF protein prevent C/EBP-mediated activation by interacting directly with C/EBP family members. Similar upregulation of C/EBP expression has been reported for other viruses, including hepatitis C virus, Kaposi’s sarcoma-associated herpes virus, and human immunodeficiency virus [49–51]. These findings show that dysregulation of C/EBP pathways are common among different viruses, suggesting that these activities are critical for viral persistence and oncogenesis.
Accumulating evidences show that HBZ’s oncogenic function can be attributed, at least in part, to its selective regulation of multiple signaling pathways in ATL [13–15, 30, 31]. For example, HBZ inactivates classical NF-κB signaling without inhibiting the alternative pathway, helping cells to evade senescence and supporting cell proliferation [13, 52]. Similarly, the negative effects of transcription factors which include ATF3, Wnt5a, and Smad3, were impeded by HBZ, leaving these factors to elude host immune attack and promote cell proliferation [14, 15, 30]. In this study, we found that HBZ selectively impaired the growth suppression function of C/EBPα, rendering the immunosuppressive and anti-apoptotic effect of C/EBPα predominant. HTLV-1 might escape from host immune surveillance and induce cell proliferation by thus selectively modulating signaling pathways, promoting viral reproduction, and also ATL.
It has been reported that HBZ is not able to form stable homodimers and is therefore dependent on heterodimerization with other proteins to control gene transcription . Thus, the function of HBZ depends, at least in part, on its binding partner. Indeed, HBZ selectively suppressed the classical NF-κB pathway through inhibiting DNA binding of p65 as well as PDLIM2-dependent p65 degradation. The specificity of PDLM2 E3 ligase in targeting p65 protein, but not p52 of the alternative pathway, may possibly explain why HBZ selectively inhibits the classical pathway of NF-κB . Similarly, we showed in this study that HBZ inhibited C/EBPα signaling via recruitment of Smad3. Because the association with Smad proteins is crucial for C/EBPα in determining its target genes as well as transcriptional outcome, it is likely that the function of HBZ-Smad3-C/EBPα complexes depends on the capacity of HBZ to recruit Smad3-C/EBPα heterodimers onto the DNA target [32, 54].
We showed that HBZ impaired the growth suppression function of C/EBP signaling by physically interacting with C/EBPα. HTLV-1 may take advantage of this mechanism to allow the infected cells to proliferate in vivo.
Cell culture, mice, and clinical samples
293T, Hela, and HepG2 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. HTLV-1 immortalized cell lines (MT-4), ATL cell lines (MT-1, ATL-2, ATL-43T, ED, and TL-Om1), and T-cell lines not infected with HTLV-1 (Jurkat) were cultured in RPMI 1640 supplemented with 10% FBS and antibiotics. Kit 225 cells stably expressing HBZ were maintained as described previously . C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan). Transgenic HBZ mice expressing HBZ specifically in CD4+ cells have been described . Peripheral blood mononuclear cells (PBMCs) were isolated from ATL patients (n = 6), and healthy volunteers (n = 3). Details of clinical samples are shown in Additional file 3: Table S1.The study of clinical samples was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Institutional Review Board of Kyoto University (844 and E-921). All patients provided written informed consent for the collection of samples and subsequent analysis.
The pC/EBP-Luc construct contains three tandem C/EBP binding sites and was purchased from Stratagene (Heidelberg, Germany). phRL-TK was purchased from Promega (Madison, WI). Reporter vector pLTR-Luc as well as expression plasmids for Tax, Smad3, HBZ, and HBZ deletion mutants were prepared as previously described [7, 13, 14]. Expression vectors for C/EBPα and its deletion mutants were generated by PCR.
Jurkat cells were plated on 6-well plates at 3.5×105 cells per well. After 24 hours, cells were transfected with the indicated luciferase plasmid DNA. Forty-eight hours after transfection, a luciferase reporter assay was performed as previously described . For the C/EBPα reporter assay, the CEBPA gene promoter was cloned into the pGL4.1 vector. Luciferase values were normalized to renilla luciferase and expressed as the mean of a triplicate set of experiments ± SD.
Immunoprecipitation and immunoblotting
293T cells were transfected with the indicated combinations of expression vectors by TransIT-LT1 (Mirus, Madison, WI). Tagged proteins were immunoprecipitated by anti–c-Myc (clone 9E10, Sigma-Aldrich, St Louis, MO), anti-HA (12CA5, Roche, Mannheim, Germany) or anti-FLAG M2 (Sigma-Aldrich) antibodies, and analyzed by Western blot. Serial immunoprecipitation was performed as described previously . Other antibodies used were as follows: anti-mouse immunoglobulin G (IgG), and anti-rabbit IgG were from GE Healthcare Life Sciences, and anti-C/EBPα from Santa Cruz Biotechnology (Santa Cruz, CA).
Hela cells were transfected with expression vectors using TransIT-LT1. Forty-eight hours after transfection, HBZ protein was detected using anti–c-MYC Cy3 (clone 9E10, Sigma-Aldrich). C/EBPα was detected using anti–FLAG-biotin (Sigma-Aldrich) and secondary Streptavidin-Alexa 488 antibody (Invitrogen, Carlsbad, CA). Fluorescence was observed with a confocal microscope system (Leica, Wetzlar, Germany) as described previously .
Chromatin immunoprecipitation assay
293T cells were transfected with the HBZ and C/EBPα expression vectors together with pC/EBP-Luc reporter vector. Forty-eight hours after transfection, chromatin immunoprecipitation (ChIP) assay was performed as previously described . Precipitated DNA was amplified by PCR using primers specific for the pC/EBP-Luc plasmid. Sequences for the primer set were 5′-TCACTGCATTCTAGTTGTGG-3′ and 5′-CCATCCTCTAGAGGATAGA-3′.
Semiquantitative RT-PCR and quantitative real-time PCR
Total RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacturer’s instructions. We reverse transcribed total RNA into single-stranded cDNA with SuperScript III reverse transcriptase (Invitrogen). For semiquantitative PCR, cDNA was amplified by increasing PCR cycles using forward (F) and reverse (R) primers specific to the target genes. In the real-time PCR experiment, cDNA product was quantified with Power SYBR Green PCR Master Mix and StepOnePlus Real Time PCR System (Life technologies). Endogenous β-actin mRNA was quantified to normalize the amount of cDNA load. The specific primers used can be found in Additional file 4: Table S2.
The tissue specimens were obtained from human lymph nodes filed at the Department of Pathology at Kurume University. Tissue samples were fixed in 10% formalin in phosphate buffer and then embedded in paraffin and analyzed by immunohistochemical methods to determine C/EBPα expression. Images were captured using a Provis AX80 microscope equipped with an OLYMPUS DP70 digital camera, and detected using a DP manager system (Olympus, Tokyo, Japan). The study of clinical samples was approved by the local research ethics committee of Kurume University.
Small interfering RNA (siRNA) transfection
siRNA targeted to human Smad3 was synthesized according to a previous report . HepG2 cells were transfected with expression vectors and siRNA using TransIT-LT1 according to the manufacturer’s instructions. RT-PCR detected SMAD3 48 hours after transfection.
Retroviral constructs and transduction
pGCDNsamI/NGFR-HBZ and pGCDNsamI/GFP-C/EBPα retroviral constructs were generated by cloning HBZ and C/EBPα cDNA into the pGCDNsamI/NGFR and pGCDNsamI/GFP vectors respectively. Transfection of Plat-E packaging cell line was performed as described . Mouse splenocytes were enriched for CD25-CD4+ cells with a CD4 T lymphocyte enrichment set (BD Biosciences) with the addition of biotinylated anti-CD25 antibody (BD Biosciences), and activated by APCs in the presence of anti-CD3 antibody and human rIL-2 in 12-well plates. After 24 hours, activated T cells were transduced with viral supernatant and polybrene, and centrifuged at 3,000 rpm for 60 minutes. Cells were subsequently cultured in medium supplemented with rIL-2.
Flow cytometric analysis
Murine cells were washed with PBS containing 1% FBS. After centrifugation, cells were treated with APC-conjugated anti-human NGFR antibody (BD Biosciences) for 30 minutes. After being washed with PBS, the cells were analyzed with a flow cytometer (BD FACSCanto II, BD Biosciences).
Statistical analyses were performed using the unpaired Student t test.
This work was supported by a grant from National Natural Science Foundation of China to TZ (No.31200128); a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan to MM; a grant from the Sciences Foundation of Zhejiang Normal University to TZ; and a grant from Technology Foundation for Selected Overseas Chinese Scholar to TZ.
- Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977, 50: 481-492.PubMedGoogle Scholar
- Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980, 77: 7415-7419. 10.1073/pnas.77.12.7415.PubMed CentralView ArticlePubMedGoogle Scholar
- Journo C, Douceron E, Mahieux R: HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol. 2009, 4: 425-440. 10.2217/fmb.09.13.View ArticlePubMedGoogle Scholar
- Grassmann R, Aboud M, Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene. 2005, 24: 5976-5985. 10.1038/sj.onc.1208978.View ArticlePubMedGoogle Scholar
- Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007, 7: 270-280. 10.1038/nrc2111.View ArticlePubMedGoogle Scholar
- Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM: The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002, 76: 12813-12822. 10.1128/JVI.76.24.12813-12822.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006, 103: 720-725. 10.1073/pnas.0507631103.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao T, Matsuoka M: HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol. 2012, 3: 247-PubMed CentralView ArticlePubMedGoogle Scholar
- Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R: HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis. J Infect Dis. 2012, 205: 82-86. 10.1093/infdis/jir708.PubMed CentralView ArticlePubMedGoogle Scholar
- Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard JM, et al: Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood. 2009, 114: 2427-2438. 10.1182/blood-2008-09-179879.PubMed CentralView ArticlePubMedGoogle Scholar
- Lemasson I, Lewis MR, Polakowski N, Hivin P, Cavanagh MH, Thebault S, Barbeau B, Nyborg JK, Mesnard JM: Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J Virol. 2007, 81: 1543-1553. 10.1128/JVI.00480-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsumoto J, Ohshima T, Isono O, Shimotohno K: HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene. 2005, 24: 1001-1010. 10.1038/sj.onc.1208297.View ArticlePubMedGoogle Scholar
- Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M: Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood. 2009, 113: 2755-2764. 10.1182/blood-2008-06-161729.View ArticlePubMedGoogle Scholar
- Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, Matsuoka M: HTLV-1 bZIP factor enhances TGF-beta signaling through p300 coactivator. Blood. 2011, 118: 1865-1876. 10.1182/blood-2010-12-326199.PubMed CentralView ArticlePubMedGoogle Scholar
- Ma G, Yasunaga J, Fan J, Yanagawa S, Matsuoka M: HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene. 2012, 32: 4222-4230.View ArticlePubMedGoogle Scholar
- Ramji DP, Foka P: CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002, 365: 561-575.PubMed CentralView ArticlePubMedGoogle Scholar
- Nerlov C: The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007, 17: 318-324. 10.1016/j.tcb.2007.07.004.View ArticlePubMedGoogle Scholar
- Tsukada J, Yoshida Y, Kominato Y, Auron PE: The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine. 2011, 54: 6-19. 10.1016/j.cyto.2010.12.019.View ArticlePubMedGoogle Scholar
- Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997, 94: 569-574. 10.1073/pnas.94.2.569.PubMed CentralView ArticlePubMedGoogle Scholar
- Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG: Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res. 2002, 62: 528-534.PubMedGoogle Scholar
- Fuchs O: Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha). 2007, 53: 97-108.Google Scholar
- Chapiro E, Russell L, Radford-Weiss I, Bastard C, Lessard M, Struski S, Cave H, Fert-Ferrer S, Barin C, Maarek O, et al: Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood. 2006, 108: 3560-3563. 10.1182/blood-2006-03-010835.View ArticlePubMedGoogle Scholar
- Paz-Priel I, Ghosal AK, Kowalski J, Friedman AD: C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters. Leukemia. 2009, 23: 365-374. 10.1038/leu.2008.297.PubMed CentralView ArticlePubMedGoogle Scholar
- Pise-Masison CA, Dittmer J, Clemens KE, Brady JN: Physical and functional interaction between the human T-cell lymphotropic virus type 1 Tax1 protein and the CCAAT binding protein NF-Y. Mol Cell Biol. 1997, 17: 1236-1243.PubMed CentralView ArticlePubMedGoogle Scholar
- Hivin P, Gaudray G, Devaux C, Mesnard JM: Interaction between C/EBPbeta and Tax down-regulates human T-cell leukemia virus type I transcription. Virology. 2004, 318: 556-565. 10.1016/j.virol.2003.10.027.View ArticlePubMedGoogle Scholar
- Tsukada J, Misago M, Serino Y, Ogawa R, Murakami S, Nakanishi M, Tonai S, Kominato Y, Morimoto I, Auron PE, Eto S: Human T-cell leukemia virus type I Tax transactivates the promoter of human prointerleukin-1beta gene through association with two transcription factors, nuclear factor-interleukin-6 and Spi-1. Blood. 1997, 90: 3142-3153.PubMedGoogle Scholar
- Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O’Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN: Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009, 113: 4016-4026. 10.1182/blood-2008-08-175901.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, et al: Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012, 21: 121-135. 10.1016/j.ccr.2011.12.015.View ArticlePubMedGoogle Scholar
- Grant C, Nonnemacher M, Jain P, Pandya D, Irish B, Williams SC, Wigdahl B: CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology. 2006, 348: 354-369. 10.1016/j.virol.2005.12.024.View ArticlePubMedGoogle Scholar
- Hagiya K, Yasunaga J, Satou Y, Ohshima K, Matsuoka M: ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology. 2011, 8: 19-10.1186/1742-4690-8-19.PubMed CentralView ArticlePubMedGoogle Scholar
- Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, Shimizu K, Ohshima K, Green PL, Ohkura N, et al: HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. Plos Pathogens. 2011, 7: e1001274-10.1371/journal.ppat.1001274.PubMed CentralView ArticlePubMedGoogle Scholar
- Choy L, Derynck R: Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem. 2003, 278: 9609-9619. 10.1074/jbc.M212259200.View ArticlePubMedGoogle Scholar
- Nerlov C: C/EBPs: recipients of extracellular signals through proteome modulation. Curr Opin Cell Biol. 2008, 20: 180-185. 10.1016/j.ceb.2008.02.002.View ArticlePubMedGoogle Scholar
- Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M: APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 2010, 84: 7278-7287. 10.1128/JVI.02239-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsuoka M: Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology. 2005, 2: 27-10.1186/1742-4690-2-27.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshida M: Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001, 19: 475-496. 10.1146/annurev.immunol.19.1.475.View ArticlePubMedGoogle Scholar
- Mulloy JC, Kislyakova T, Cereseto A, Casareto L, LoMonico A, Fullen J, Lorenzi MV, Cara A, Nicot C, Giam C, Franchini G: Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol. 1998, 72: 8852-8860.PubMed CentralPubMedGoogle Scholar
- Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, et al: Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol. 1991, 3: 761-767. 10.1093/intimm/3.8.761.View ArticlePubMedGoogle Scholar
- Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK, Tenen DG, Behre G: Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 2010, 115: 1768-1778. 10.1182/blood-2009-08-240101.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu GD, Leung CH, Yan B, Tan CM, Low SY, Aung MO, Salto-Tellez M, Lim SG, Hooi SC: C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology. 2010, 139: 632-643. 10.1053/j.gastro.2010.03.051. 643 e631-634View ArticlePubMedGoogle Scholar
- White JD, Zaknoen SL, Kasten-Sportes C, Top LE, Navarro-Roman L, Nelson DL, Waldmann TA: Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer. 1995, 75: 1598-1607. 10.1002/1097-0142(19950401)75:7<1598::AID-CNCR2820750708>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Nicot C: Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005, 78: 232-239. 10.1002/ajh.20307.View ArticlePubMedGoogle Scholar
- Sugata K, Satou Y, Yasunaga J, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, Matsuoka M: HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood. 2012, 119: 434-444. 10.1182/blood-2011-05-357459.PubMed CentralView ArticlePubMedGoogle Scholar
- Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N: PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Proc Natl Acad Sci USA. 2009, 106: 15807-15812. 10.1073/pnas.0908805106.PubMed CentralView ArticlePubMedGoogle Scholar
- Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, et al: Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 2010, 32: 790-802. 10.1016/j.immuni.2010.05.010.View ArticlePubMedGoogle Scholar
- Choi BH, Park GT, Rho HM: Interaction of hepatitis B viral X protein and CCAAT/ enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem. 1999, 274: 2858-2865. 10.1074/jbc.274.5.2858.View ArticlePubMedGoogle Scholar
- Bristol JA, Robinson AR, Barlow EA, Kenney SC: The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol. 2010, 84: 12362-12374. 10.1128/JVI.00712-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu Y, Nonnemacher MR, Wigdahl B: CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection. Future Microbiol. 2009, 4: 299-321. 10.2217/fmb.09.4.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang SE, Wu FY, Yu Y, Hayward GS: CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi’s sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol. 2003, 77: 9590-9612. 10.1128/JVI.77.17.9590-9612.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K: HCV infection induces inflammatory cytokines and chemokines mediated by the cross-talk between hepatocytes and stellate cells. J Virol. 2013, 87: 8169-8178. 10.1128/JVI.00974-13.PubMed CentralView ArticlePubMedGoogle Scholar
- Fields J, Gardner-Mercer J, Borgmann K, Clark I, Ghorpade A: CCAAT/enhancer binding protein beta expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J Neurochem. 2011, 118: 93-104. 10.1111/j.1471-4159.2011.07203.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhi HJ, Yang LP, Kuo YL, Ho YK, Shih HM, Giam CZ: NF-kappa B Hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ. Plos Pathogens. 2011, 7: e1002025-10.1371/journal.ppat.1002025.PubMed CentralView ArticlePubMedGoogle Scholar
- Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Duc Dodon M: HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). Retrovirology. 2007, 4: 92-10.1186/1742-4690-4-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J: C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006, 10: 203-214. 10.1016/j.ccr.2006.07.019.View ArticlePubMedGoogle Scholar
- Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M: HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog. 2013, 9: e1003630-10.1371/journal.ppat.1003630.PubMed CentralView ArticlePubMedGoogle Scholar
- Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, et al: Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res. 2005, 33: e131-10.1093/nar/gni130.PubMed CentralView ArticlePubMedGoogle Scholar
- Morita S, Kojima T, Kitamura T: Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000, 7: 1063-1066. 10.1038/sj.gt.3301206.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.